

AWARD NUMBER: W81XWH-14-1-0591

TITLE: Electric Field Stimulation Enhances Healing of Post-Traumatic Osteoarthritic Cartilage

PRINCIPAL INVESTIGATOR: Chloë Bulinski, PhD

CONTRACTING ORGANIZATION:
Trustees of Columbia University in the City of New York
New York NY 10027-6944

REPORT DATE: October 2016

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE October 2016		2. REPORT TYPE Annual		3. DATES COVERED 30 Sep 2015 -29 Sep 2016	
4. TITLE AND SUBTITLE Electric Field Stimulation Enhances Healing of Post-Traumatic Osteoarthritic Cartilage				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-14-1-0591	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Chloë Bulinski, PhD E-Mail: jcb4@columbia.edu				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Trustees of Columbia University in the City of New York 804A Fairchild Center M.C. 2450 New York, NY 10027				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT Introduced early into the course of PTOA, electromagnetic energy may have the benefit of maintaining function in highly active individuals. Thus, electromagnetic fields are particularly suited to young active populations and for the military, in whom, PTOA is an unfitting condition and for whom joint replacement is an unsuitable salvage option. If successful, electromagnetic energy will maintain joint function and avoid surgery. The benefits to retain one's own joint are obvious. Electromagnetic energy devices are FDA approved for bone healing and have been use for 30 years in thousands of patients with an extremely low frequency of adverse events. So the risks of treatment are quite minimal. The clinical applications of electromagnetic field therapy would especially appealing to the young and middle aged patients with early PTOA who are symptomatic from pain and limited function. Benefits would be the reduction of pain and inflammation with concomitant improved function and also preservation of cartilage and bone with the potential avoidance, or at least delay, of joint replacement. Risks of this treatment would be so infrequent as to be anecdotal.					
15. SUBJECT TERMS Cartilage explants, fibrin glue, collagen, canine model system					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT UU	18. NUMBER OF PAGES 16	19a. NAME OF RESPONSIBLE PERSON USAMRMC
a. REPORT U	b. ABSTRACT U	c. THIS PAGE U			19b. TELEPHONE NUMBER (include area code)

Table of Contents

	<u>Page</u>
1. Introduction.....	1
2. Key Words	1
3. Accomplishments	1
4. Impact	5
5. Changes/Problems.....	6
6. Products	7
7. Participants & Other Collaborating Organizations	10
8. Special Reporting Requirements	12
9. Appendices.....	12

1. **INTRODUCTION:** Narrative that briefly (one paragraph) describes the subject, purpose and scope of the research.

The causative role of trauma in the development of osteoarthritis (OA) has been well-described, and there are as yet no effective strategies for preventing the inflammation and apoptosis that develop post-trauma. Thus, injuries to joints caused by either sports or combat almost always develop into full-blown OA. Both basic and translational studies are needed to establish and therapeutically target the progression of traumatic injury into OA; a vital part of these studies involves use of animal models. To further our main objective of substantially improving the poor healing of OA defects in cartilage, we propose to develop strategies in which our model system is the dog, and we use electric fields (EFs) to direct movement of cartilage precursor cells to the site of OA damage, and to optimize differentiation at the site of injury. As precursor cells we will utilize either endogenous canine chondrocytes or the clinically relevant canine cartilage stem cells called Synovium-Derived Stem Cells (SDSCs). Moreover, we will develop and optimize matrix components that we will introduce into the site of injury in order to further enhance precursor cell motility and chondrogenic differentiation. We propose that our strategy will promote healing of articular cartilage defects in dogs. Further, we are confident that achieving healing in the canine system will both be useful for treating canines in the military and will also allow these strategies to be translatable to humans.

2. **KEYWORDS:** Provide a brief list of keywords (limit to 20 words).

Cartilage explants, fibrin glue, collagen, canine model system

3. **ACCOMPLISHMENTS:** The PI is reminded that the recipient organization is required to obtain prior written approval from the awarding agency grants official whenever there are significant changes in the project or its direction.

What were the major goals of the project?

List the major goals of the project as stated in the approved SOW. If the application listed milestones/target dates for important activities or phases of the project, identify these dates and show actual completion dates or the percentage of completion.

Specific Aim 1: Apply EFs to canine cartilage explants to measure cell motility/ recruitment into an experimental wound.

Major Task 1: Perform *in vitro* studies of canine cartilage explants, measuring cell motility/ recruitment into an experimental wound.

Specific Aim 2: Apply EFs to ‘wounded’ canine cartilage explants in the presence of labeled synovium-derived stem cells (SDSCs).

Major Task 2: Perform *in vitro* studies of canine cartilage explants to which canine SDSCs have been added, measuring cell motility/ recruitment into an experimental wound.

Specific Aim 3: Perform *in vivo* studies investigating the efficacy of DC EFs for cartilage repair in a canine knee defect model.

Major Task 3: Make cartilage wounds in animals, surgically implant electrodes, and allow healing in the presence or absence of applied EFs.

For this reporting period describe: 1) major activities; 2) specific objectives; 3) significant results or key outcomes, including major findings, developments, or conclusions (both positive and negative); and/or 4) other achievements. Include a discussion of stated goals not met. Description shall include pertinent data and graphs in sufficient detail to explain any significant results achieved. A succinct description of the methodology used shall be provided. As the project progresses to completion, the emphasis in reporting in this section should shift from reporting activities to reporting accomplishments.

During Year 2, since **Specific Aim 1** had been completed, all that remained was to obtain all animal approvals for the live animal work at the University of Missouri in Aim 3.

Accordingly, in Months 18-21 (e.g., March – June, 2016) we obtained Local IRB/IACUC Approval and HRPO/ACURO Approval (for Tasks in Aim 3).

We focused on work in **Specific Aim 2**, however – we have abbreviated each of the tasks in the original SOW and described the work on each:

Specific Aim 2: Apply EFs to ‘wounded’ canine cartilage explants in the presence of labeled synovium-derived stem cells (SDSCs).

Major Task 2: Perform in vitro studies of canine cartilage explants to which canine SDSCs have been added, measuring cell motility/ recruitment into an experimental wound.

Subtask 1: Apply a range of EFs and elapsed times to ‘wounded’ cartilage explant system; measure persistence of healing, including cell density and level of chondrogenic differentiation.

Subtask 2: Design the electrostimulator system for in vivo studies on canine knee cartilage, test it in vitro and determine best practices for surgical placement in dogs.

Subtask 3: Track cells during and following healing, to measure the extent to which SDSCs fill the wound contribute to its healing.

We have devised an in vitro model of 3D cartilage wound-healing that is directly translatable to our Year 3 experiments in vivo. Briefly, our model uses cartilage explants (we call these ‘chondrobagels’) that have the exact dimensions of the in vivo ‘wounds’ we will make in the canine trochlear groove. During the past year, we have optimized the 1) matrix, 2) stem cells, and 3) timing of wound-healing +/- electric field induction, 4) parameters of the electric field and design of electrodes and electrostimulators as described below and illustrated in the Appendix of Figures and Abstracts.

To address tasks **Subtasks 1-3**, we first tested a variety of matrix components with which to fill the hollow center of each explant, in order to identify a matrix that would support cell motility and chondrogenic differentiation, but would also integrate adequately with the surrounding explant. In Year 1, we had a tremendous problem because the tension generated by the cells’ motility caused the matrix to contract and pull away from the explant edges. Year 1 experiments demonstrated that the matrix was neither sufficiently rigid nor cross-linked; hence we spent considerable effort in Year 2 remedying this problem.

Although we are still quantifying our results, we have managed to create the optimal matrix, which consists of: Type I collagen, fibrinogen/thrombin (i.e., to generate ‘Fibrin Glue’), the fibrinolysis inhibitor, aprotinin, the biological cross-linker, genipin, and the glycosaminoglycan components, hyaluronic acid and chondroitin sulfate. Using three experiments to test each set of concentrations, we first evaluated the concentration of genipin cross-linker that maintained

the integrity of the collagen/fibrin matrix and best supported cell viability. Since we are preparing a matrix that will eventually be injected into canine trochlear groove cartilage ‘holes,’ we used the genipin in a manner that had not been reported by other groups. That is, we mixed all the components with genipin and cells and placed this in the explant. This is different from the strategy used by others; all other published studies included genipin in the culture medium subsequently. Our technique is readily translatable to the in vivo use of genipin in the matrix. As described in the Appendix, we found that the optimized concentration of genipin for maintaining matrix and keeping >99% of cells viable was 220 μ M.

Next, we optimized the culture, processing and labeling of stem cells (synovium-derived stem cells, or SDSCs). This is vital in order to yield the appropriate degree of cellularity as well as the cells’ ability as synthesis and maintenance of cartilage matrix components. We conjectured that the density of cells in the matrix filling the center of the explant should closely approximate the cell density in the surrounding explant; we found this to be the case. Accordingly, we routinely labeled SDSCs with diI in order to monitor them, and then used them at density such that $\sim 2.5 \times 10^5$ cells were placed in the matrix applied to the center of each explant (this is a cell density of $\sim 4 \times 10^6$ cells/mL). Again, we will quantify the cells differentiation during Year 3 (see upcoming plans section); initial qualitative measures suggest that the cell density and level of differentiation and integration during either 56-day or 70-day wound-healing periods (commensurate with the protocol proposed for in vivo studies) occurred at an excellent level.

To address **Subtask 3**, we used the chambers we had prepared for Specific Aim 1 (see Appendix, Stefani et al. abstract, Figure 1), as well as a new chamber design utilizing Transwells and allowing long-term access and electric field (EF) application (shown in the Appendix, page 7). Since we determined that EFs applied over a short term induced cell motility and over a longer term induced differentiation, we showed that the Transwell chamber allows long term sterile manipulation of the EF application, including pulses on/off, 8-week differentiation periods, and alteration in the field (from DC to EMF fields as cells switched from motility to differentiation. During Year 2, the chamber we redesigned was also shown to allow application to as many explants as needed at one time, and these results are described in the second Appendix paper and data from Robert Stefani, the research assistant who works full time on this project. Everything about this chamber and these fields is also translatable to the in vivo canine wound-healing we will embark on during Year 3. Our co-Investigator, Dr. Roy Aaron, and our Consultant, Ruggero Cadossi, have experience with the in vivo application of electrostimulators in humans (see picture for the general scheme) and in sheep (in which the stimulator is placed in a vest/harness that the dog wears). The EF currently optimized in the Transwell apparatus will be applied via the portable stimulator in Year 3.



← Electrical Stimulator for underlying knee cartilage (model for humans is pictured)

What opportunities for training and professional development has the project provided?

If the project was not intended to provide training and professional development opportunities or there is nothing significant to report during this reporting period, state “Nothing to Report.”

Describe opportunities for training and professional development provided to anyone who worked on the project or anyone who was involved in the activities supported by the project. "Training" activities are those in which individuals with advanced professional skills and experience assist others in attaining greater proficiency. Training activities may include, for example, courses or one-on-one work with a mentor. "Professional development" activities result in increased knowledge or skill in one's area of expertise and may include workshops, conferences, seminars, study groups, and individual study. Include participation in conferences, workshops, and seminars not listed under major activities.

Work on the project provided a major amount of the Ph.D. training of the graduate student who has been working on the project, Robert Stefani, M.S. In addition, an undergraduate, Ms. Carina Sirochinsky, a Hunter College McCauley Scholar who worked on the project in Summer 2016 as part of the Amgen Summer Program here at Columbia University, received training and mentored work with the PI. Both are participating in the upcoming ORS Meeting, where they will present posters (see Published Abstracts in the Appendix); this is a tremendous addition to their professional development. Further, Ms. Sirochinsky is planning to study for a Ph.D. in Material Science or Biomedical Engineering, since her focus is on biomaterials in the project.

How were the results disseminated to communities of interest?

If there is nothing significant to report during this reporting period, state "Nothing to Report."

Describe how the results were disseminated to communities of interest. Include any outreach activities that were undertaken to reach members of communities who are not usually aware of these project activities, for the purpose of enhancing public understanding and increasing interest in learning and careers in science, technology, and the humanities.

In addition to the two ORS presentations, made in order to share results with the orthopedic research community, the PI has given several talks to college students (Columbia Science Research Fellows, Biological Sciences Incoming Class of Ph.D. students) and the PI and Ms. Sironchinsky also presented this work at the ABRCMS (Annual Biomedical Research Conference for Minority Students). In this way, many young students new to science were introduced to the application of cell motility and differentiation studies to solving problems in human health.

What do you plan to do during the next reporting period to accomplish the goals?

If this is the final report, state "Nothing to Report."

Describe briefly what you plan to do during the next reporting period to accomplish the goals and objectives.

In Year 3 of our project, we will quantify the extent of chondrogenic differentiation in all the different matrix mixtures during the 8- and 10-week differentiation period. We will assay their level of differentiation via GAG, collagen, and measure their level of integration with the surrounding explant optically and through mechanical assays. In the latter assay, we will compare them to explant cylinders of the same dimensions, but without the punched out and reconstituted lumen.

In late Fall, we will also instigate the in vivo canine experiments. We are currently making arrangements to travel to our Partnering P-I's (Dr. Cook's) laboratory with cells, all stocks of matrix Components, and the electrodes designed by our other Partnering P-I's (Dr. Aaron).

We will carry out these experiments (+/- electric field, +/- SDSCs) as described in our proposal. Importantly, we have already obtained approval of our ACURO (in June, 2016).

We are presenting our data thus far at ORS, and based upon quantification and also comments of colleagues from those presentations, we will revise our two manuscripts describing our results. We are excited - and ready – to perform the in vivo experiments, based upon our strong results on the in vitro model we developed for 3D cartilage wound healing.

4. **IMPACT:** Describe distinctive contributions, major accomplishments, innovations, successes, or any change in practice or behavior that has come about as a result of the project relative to:

What was the impact on the development of the principal discipline(s) of the project?

If there is nothing significant to report during this reporting period, state “Nothing to Report.”

Describe how findings, results, techniques that were developed or extended, or other products from the project made an impact or are likely to make an impact on the base of knowledge, theory, and research in the principal disciplinary field(s) of the project. Summarize using language that an intelligent lay audience can understand (Scientific American style).

Thus far in the project, we have identified appropriate matrix and cell conditions as well as appropriate electric field parameters to substantially ‘heal’ in vitro wounds. These results have a high impact on the field, as this is a system that we developed and it is substantially different from other models of cartilage repair. Also, given the success of our in vitro strategies, we feel that we have a good chance of success in vivo, as well. If the success of our 3D in vitro wound-healing system is mimicked in vivo in Year 3, our work will have a transformative impact on the field.

What was the impact on other disciplines?

If there is nothing significant to report during this reporting period, state “Nothing to Report.”

Describe how the findings, results, or techniques that were developed or improved, or other products from the project made an impact or are likely to make an impact on other disciplines.

In other fields such as cell biology, investigators have had difficulty coming up with 3D models that can be used to study cell motility, cell differentiation, wound-healing, etc. Our system satisfies most of the criteria demanded for these types of investigations and in addition, our model system is amenable to real-time observation of the migrating cells. Thus, our system has been noted by cell and developmental biologists for its ingenuity, health impact and convenience.

What was the impact on technology transfer?

If there is nothing significant to report during this reporting period, state “Nothing to Report.”

Describe ways in which the project made an impact, or is likely to make an impact, on commercial technology or public use, including:

- *transfer of results to entities in government or industry;*
- *instances where the research has led to the initiation of a start-up company; or*
- *adoption of new practices.*

Nothing to Report

What was the impact on society beyond science and technology?

If there is nothing significant to report during this reporting period, state “Nothing to Report.”

Describe how results from the project made an impact, or are likely to make an impact, beyond the bounds of science, engineering, and the academic world on areas such as:

- *improving public knowledge, attitudes, skills, and abilities;*
- *changing behavior, practices, decision making, policies (including regulatory policies), or social actions; or*
- *improving social, economic, civic, or environmental conditions.*

Nothing to Report

5. **CHANGES/PROBLEMS:** The PD/PI is reminded that the recipient organization is required to obtain prior written approval from the awarding agency grants official whenever there are significant changes in the project or its direction. If not previously reported in writing, provide the following additional information or state, “Nothing to Report,” if applicable:

Changes in approach and reasons for change

Describe any changes in approach during the reporting period and reasons for these changes. Remember that significant changes in objectives and scope require prior approval of the agency.

Nothing to Report

Actual or anticipated problems or delays and actions or plans to resolve them

Describe problems or delays encountered during the reporting period and actions or plans to resolve them.

One can never anticipate all problems that may arise. Our main concerns here are two-fold:

- 1) We need to culture a huge number of canine SDSCs ($\sim 50 \times 10^6$) for the in vivo experiments, and since these cells need to be differentiation-competent (therefore low passage) and ready on the day when the canine surgical procedures are to be carried out, this is a logistical challenge. However, we are very experienced at cell culture and manipulation and specifically, we have quantified the differentiation capacity of canine SDSCs up to 4 passages in previous work, so this should be doable.
- 2) One can never assume the fidelity with which our 3D in vitro wound-healing system will be mimicked in vivo. Still, our work to date suggests that we have identified appropriate matrix and cell conditions as well as appropriate electric field parameters, so we feel that we have a good chance of success. Besides, this is really a high risk – but high reward study that may have translational impact on canines and humans. The potential for benefit is not to be minimized.

Changes that had a significant impact on expenditures

Describe changes during the reporting period that may have had a significant impact on expenditures, for example, delays in hiring staff or favorable developments that enable meeting objectives at less cost than anticipated.

Nothing to Report

Significant changes in use or care of human subjects, vertebrate animals, biohazards, and/or select agents

Describe significant deviations, unexpected outcomes, or changes in approved protocols for the use or care of human subjects, vertebrate animals, biohazards, and/or select agents during the reporting period. If required, were these changes approved by the applicable institution committee (or equivalent) and reported to the agency? Also specify the applicable Institutional Review Board/Institutional Animal Care and Use Committee approval dates.

Significant changes in use or care of human subjects

Not Applicable

Significant changes in use or care of vertebrate animals

No Changes

Significant changes in use of biohazards and/or select agents

Not Applicable

6. PRODUCTS: List any products resulting from the project during the reporting period. If there is nothing to report under a particular item, state “Nothing to Report.”

- Publications, conference papers, and presentations**

Report only the major publication(s) resulting from the work under this award.

Journal publications. *List peer-reviewed articles or papers appearing in scientific, technical, or professional journals. Identify for each publication: Author(s); title; journal; volume; year; page numbers; status of publication (published; accepted, awaiting publication; submitted, under review; other); acknowledgement of federal support (yes/no).*

Nothing to Report

Books or other non-periodical, one-time publications. *Report any book, monograph, dissertation, abstract, or the like published as or in a separate publication, rather than a periodical or series. Include any significant publication in the proceedings of a one-time conference or in the report of a one-time study, commission, or the like. Identify for each one-time publication: author(s); title; editor; title of collection, if applicable; bibliographic information; year; type of publication (e.g., book, thesis or dissertation); status of publication (published; accepted, awaiting publication; submitted, under review; other); acknowledgement of federal support (yes/no).*

1. Sirochinsky et al (see Appendix): “Effect of Genipin on Engineered Tissue Integration in an Injectable Cell-Seeded, Collagen and Fibrin Glue Matrix” ORS 2017 Abstracts. Accepted for Presentation at Annual Meeting in San Diego in March, 2017
2. Stefani et al. (see Appendix): “Electric Field Modulation of Synovial Fibroblast Migration for Cartilage Repair” ORS 2017 Abstracts. Accepted for Presentation at Annual Meeting in San Diego in March, 2017

O

Other publications, conference papers and presentations. *Identify any other publications, conference papers and/or presentations not reported above. Specify the status of the publication as noted above. List presentations made during the last year (international, national, local societies, military meetings, etc.). Use an asterisk (*) if presentation produced a manuscript.*

Sirochinsky, C., Pino, N., and Bulinski, J.C. “Effect of Genipin on Engineered Tissue Integration in an Injectable Cell-Seeded, Collagen and Fibrin Glue Matrix”, presented at ABRCMS in Tampa FL, November, 2016

- **Website(s) or other Internet site(s)**

List the URL for any Internet site(s) that disseminates the results of the research activities. A short description of each site should be provided. It is not necessary to include the publications already specified above in this section.

Nothing to Report

- **Technologies or techniques**
Identify technologies or techniques that resulted from the research activities. Describe the technologies or techniques were shared.

Nothing to Report

- **Inventions, patent applications, and/or licenses**
Identify inventions, patent applications with date, and/or licenses that have resulted from the research. Submission of this information as part of an interim research performance progress report is not a substitute for any other invention reporting required under the terms and conditions of an award.

Nothing to Report

- **Other Products**
Identify any other reportable outcomes that were developed under this project. Reportable outcomes are defined as a research result that is or relates to a product, scientific advance, or research tool that makes a meaningful contribution toward the understanding, prevention, diagnosis, prognosis, treatment and /or rehabilitation of a disease, injury or condition, or to improve the quality of life. Examples include:
 - *data or databases;*
 - *physical collections;*
 - *audio or video products;*
 - *software;*
 - *models;*
 - *educational aids or curricula;*
 - *instruments or equipment;*
 - *research material (e.g., Germplasm; cell lines, DNA probes, animal models);*
 - *clinical interventions;*
 - *new business creation; and*
 - *other.*

Nothing to Report

7. PARTICIPANTS & OTHER COLLABORATING ORGANIZATIONS

What individuals have worked on the project?

Provide the following information for: (1) PDs/PIs; and (2) each person who has worked at least one person month per year on the project during the reporting period, regardless of the source of compensation (a person month equals approximately 160 hours of effort). If information is unchanged from a previous submission, provide the name only and indicate “no change”.

Name: J. Chloë Bulinski

Project Role: Principal Investigator

Nearest person month worked: All of Year 2 (and up to the present)

Contribution to Project: Dr. Bulinski has trained all students, designed all experiments and participated in the set-up, analysis and troubleshooting of experiments.

Name: Clark T. Hung

Project Role: Co- Investigator

Nearest person month worked: All of Year 2 (and up to the present)

Contribution to Project: Dr. Hung has trained all students, designed all chambers and apparatus, and participated in set-up, analysis and troubleshooting of experiments.

Name: Roy Aaron

Project Role: Partnering P-I

Nearest person month worked: Year 2 - present

Contribution to Project: Dr. Aaron has participated in design and analysis of electric field application experiments.

Name: James L. Cook

Project Role: Partnering P-I

Researcher Identifier (e.g. ORCID ID):

Nearest person month worked: Year 2 - present

Contribution to Project: Dr. Cook has participated in design and functional application of 3D matrix to support cell motility. He has also supplied canine tissue used in Quarter 3 and up to the present

Name: Rob Stefani

Project Role: BME Graduate Student

Nearest person month worked: 1 months of Quarter 4 (and he will continue until at least June 1, 2017)

Contribution to Project: Mr. Stefani generated the figures for the Appendix Results and one of the abstracts therein; he has also performed the Z-stack imaging and analysis of cell densities.

Name: Carina Sirochinsky

Project Role: Hunter College McCauley Honors Undergraduate Student

Nearest person month worked: All months of Quarter 4 (and she will continue part-time, until at least May 1, 2017)

Contribution to Project: Ms. Sirochinsky generated the data and figures in one of the abstracts Results and she also performed the SDSC labeling studies and the analysis of matrix components.

Has there been a change in the active other support of the PD/PI(s) or senior/key personnel since the last reporting period?

If there is nothing significant to report during this reporting period, state "Nothing to Report."

If the active support has changed for the PD/PI(s) or senior/key personnel, then describe what the change has been. Changes may occur, for example, if a previously active grant has closed and/or if a previously pending grant is now active. Annotate this information so it is clear what has changed from the previous submission. Submission of other support information is not necessary for pending changes or for changes in the level of effort for active support reported previously. The awarding agency may require prior written approval if a change in active other support significantly impacts the effort on the project that is the subject of the project report.

Nothing to Report

What other organizations were involved as partners?

If there is nothing significant to report during this reporting period, state "Nothing to Report."

Describe partner organizations – academic institutions, other nonprofits, industrial or commercial firms, state or local governments, schools or school systems, or other organizations (foreign or domestic) – that were involved with the project. Partner organizations may have provided financial or in-kind support, supplied facilities or equipment, collaborated in the research, exchanged personnel, or otherwise contributed.

Provide the following information for each partnership:

Organization Name:

Location of Organization: (if foreign location list country)

Partner's contribution to the project (identify one or more)

- Financial support;
- In-kind support (e.g., partner makes software, computers, equipment, etc., available to project staff);
- Facilities (e.g., project staff use the partner's facilities for project activities);
- Collaboration (e.g., partner's staff work with project staff on the project);
- Personnel exchanges (e.g., project staff and/or partner's staff use each other's facilities, work at each other's site); and
- Other.

Nothing to report

8. SPECIAL REPORTING REQUIREMENTS

COLLABORATIVE AWARDS: None

Total Direct Spending Project to Date: \$235,438.39

Total Indirect Spending Project to Date: \$102,979.55

Total Spending Project to date: \$338,417.94

Current balance: \$52,721.06

See Quad Chart for more information.

QUAD CHARTS:

9. APPENDICES

Effect of Genipin on Engineered Tissue Integration in an Injectable Cell-Seeded, Collagen and Fibrin Glue Matrix

Carina Sirochinsky¹, Natalie Pino¹, Robert M. Stefani², Brendan L. Roach², Andrea R. Tan², Clark T. Hung², J. Chloe Bulinski¹

¹Department of Biological Sciences, Columbia University, New York, USA ²Department of Biomedical Engineering, Columbia University, New York, USA

Disclosures: None

INTRODUCTION: Successful engineering of the repair of osteoarthritis lesions would allow for integration between the construct and the native tissue into which it is implanted. To address the issue of tissue integration, we propose an injectable, cell-seeded matrix that contains collagen, fibrin glue, and aprotinin, structurally stabilized by genipin. Genipin, a biocompatible cross-linker, has previously been used to fix collagen-based scaffolds prior to cell-seeding or in vivo implantation [1]. Our approach is novel, as we incorporate genipin with synovium-derived stem cells (SDSCs) in the liquid matrix that subsequently polymerizes into a solid scaffold in our *in vitro* model construct. We hypothesized that the genipin would promote crosslinking between the collagen in the scaffold with that in the native tissue. The incorporation of genipin with living cells warranted a monitoring of the effect of different genipin concentrations on the viability of the SDSCs, as well as testing the effects of addition of chondroitin/hyaluronic acid into the matrix to better model the *in vivo* 3D chondrogenic environment. Upon determining the biological threshold concentration of genipin, we tested the effects of genipin on construct longevity and integration of the construct matrix with the native cartilage tissue.

METHODS: Materials: Unless otherwise noted, all materials and tissue culture solutions were obtained from Sigma Chemical or Life Technologies.

Harvest of Cells and Explants: Articular cartilage was harvested from the knee joints of freshly slaughtered 3-4 month old bovine calves, digested with collagenase IV and plated and expanded as described [2]. Biopsy punches (8 mm dia) were used to create cylinders of femoral cartilage. These cylinders were sliced into disks and a biopsy punch was used to remove a 6 mm dia section in the center of the disk (see Fig. 1), creating an explant modeling osteoarthritic lesions. Construct Creation: SDSCs were trypsinized from culture at 90% confluence and labeled with DiI solution (Molecular Probes). The following components were combined to create a liquid matrix with final concentrations as follows: Collagen type I (1 mg/mL bovine Nutragen Collagen, Advanced Biomatrix), fibrinogen (10 mg/mL), thrombin (100 un/mL), aprotinin (3000 un/mL), SDSCs (5×10^5 cells/mL), and genipin at various concentrations (0, 22, 44, 110, 220, 2200 μ M). The explant lumens were then filled with the liquid matrix (~60 μ L of matrix per explant), which was allowed to polymerize at 25°C for 30 minutes (Figure 1). Construct Culture: The constructs were cultured in CM supplemented with 10 ng/mL TGF- β 3 for the first 14 days and then in unsupplemented CM for the remainder of the study. Histology: Samples were fixed in acid formalin on day 1, day 14, day 28, day 42, and day 56 of the study to assess the cell distribution, integration with surrounding cartilage tissue, and the GAG (Alcian blue staining) and collagen (Safranin-O staining) distribution in the constructs at each time point. Imaging: Constructs were stained with DAPI nuclear stain prior to imaging. Images were taken with channels for DiI (ex/em 549/565) and DAPI (ex/em 358/461). Live/Dead assays were also carried out to monitor cell death over the course of the study. Integration monitoring: Integration between the artificial and native tissue was monitored by tracking the gap size between the matrix and explant over time as well as tracking the migration of chondrocytes out of the explant and into the lumen region.

RESULTS: Genipin concentrations from 0 μ M up to 221 μ M were tolerated by SDSCs in the matrix, yielding a uniform distribution of cells and matrix filling the lumen of the construct (Fig. 2). Higher genipin concentrations led to a change in cell morphology from fibroblastic to spherical, potentially indicating cell death; Live/Dead assays confirmed the cell viability in the samples. Samples with genipin concentrations above the tolerated level, however, showed the best construct longevity. In addition, the otherwise toxic genipin concentration had no effect on the viability of cells migrating out of the explant tissue (Figure 3). Addition of chondroitin sulfate (C6S) and HA in physiological concentrations seemed to have no apparent effect on cell viability or longevity of the construct.

DISCUSSION: We have successfully combined collagen and “Fibrin Glue” into a matrix in which SDSCs thrive and fill in the engineered ‘wound’ in the cartilage explant. Others [3] have reported in vivo incorporation of a similar matrix expected to recruit host cells into an induced cartilage defect. However, testing out similar approaches, with and without stem cells incorporated into the matrix in the lumen of the cartilage explant, we determined that the SDSCs tended to move on, and thus deform, the collagen fibers, and to degrade the fibrin, possibly via secreted metalloproteases, even in the presence of aprotinin to inhibit these enzymes. This resulted in inhomogeneous matrix in the explant lumen and poor integration with the surrounding explant cartilage tissue. Our results here demonstrate that addition of genipin to cross-link the matrix could produce a more stable, better integrated matrix. We determined conditions whereby the addition of genipin during matrix formation was compatible with SDSC viability, and the protocol we have developed appears amenable to extrapolation to an *in vivo* cartilage defect repair model.

SIGNIFICANCE: Creating an engineered tissue that successfully integrates with native cartilage in osteoarthritic joints is a major challenge that has yet to be overcome in the field of cartilage engineering. Incorporating genipin into an injectable matrix may provide a solution to this problem and allow for the development of more effective, long-term and even preventative treatments for osteoarthritis. Our results here, in developing a protocol in which stem cells, matrix components are mixed and allowed to polymerize in the lumen of a cartilage defect model are readily translatable into an *in vivo* setting or potentially into a human therapy.

ACKNOWLEDGEMENTS: CS was supported by the Amgen Summer Program at Columbia University; the project was supported by CDMRP Award # number W81XWH-14-1-0591 to JCB.

REFERENCES: [1] Lima+ J. Biomed. Mater. Res. 2008. [2] Tan+ Clin Orthop Relat Res 2011. [3] Shetty+ Orthopedics 2013.

FIGURES:





Figure 2: Genipin cross-linking of matrix: 220 μ M genipin was added to matrix mixture and SDSCs (1.7×10^5 cells/construct). Construct was imaged after 14 da. Note SDSCs (in red with DiI membrane stain) fill the lumen, All nuclei are in blue with DAPI label.




Figure 3: Genipin cross-linking at supra-toxic concentration (2.2 mM): (A) SDSCs seeded in matrix shown in red (DiI membrane stain) with SDSC and chondrocyte nuclei in blue (DAPI nuclear stain). Red fluorescence (ex/em ~549/560) in explant tissue arises from genipin crosslinking. Black/white arrows: area enlarged in 3B/3C, respectively. (B) SDSCs in the center of matrix with round morphology and are DiI stained. (C) Cells in matrix near explant tissue not DiI stained (visible with DIC) near the edges of the explant tissue presumably migrated out of the explant and into the luminal matrix.

Electric Field Modulation of Synovial Fibroblast Migration for Cartilage Repair

Robert M. Stefani¹, Brendan L. Roach¹, Amy M. Silverstein¹, Robert J. Nims¹, Jae Han Lee², Gerard A. Ateshian¹, J. Chloe Bulinski¹, Clark T. Hung¹
¹Columbia University, New York, NY, ²Vanderbilt University, Nashville, TN

Disclosures: RMS, BLR, AMS, RJN, JHL, GAA, JCB (None), CTH (7- JOR)

INTRODUCTION: As articular cartilage is not vascularized, it exhibits a poor healing capacity, creating a condition where localized regions of damage will lead to full blown osteoarthritis if untreated. Applied electric fields (EFs) can be applied *in vitro* to foster development of functional tissue grafts in culture as well as *in vivo* for promoting tissue repair. The application of EFs is already used clinically to promote wound healing of various tissues, including skin, bone and cartilage [7]. In the context of cartilage repair, the system described herein allows EF gradients to be applied to cells cultured in 3D, whereas such studies have been more typically performed in 2D [3]. The current study explores EF-induced migration (or galvanotaxis) of synovial fibroblasts in collagen gel (study 1) or on cartilage explants in which cylindrical wounds have been made to simulate cartilage injury (study 2). Synovial fibroblasts have been implicated in the limited repair response of cartilage *in situ* [5] and can be differentiated to make cartilage *in vitro* [6], making them an attractive target cell source for cartilage repair strategies.

METHODS: Chamber Design: The galvanotaxis chamber (Figure 1A) was configured to apply direct current (DC) electric fields to cylindrical cartilage tissue specimens to simulate the migration of endogenous/exogenous repair cells into a model defect (Figure 1B). A gasket between the top and bottom portion provided a tight seal and accommodated irregularly shaped specimens. The cathode (-) and anode (+) were positioned above and below the sample chamber, respectively. Study 1: Synovial fibroblasts were seeded at a density of 50,000 cells/cm² on the surface of a 2 mg/ml type I collagen gel. After an overnight pre-culture to allow adhesion, gels were placed in the chamber and exposed to 3.33mA current for either 90 or 180 min to achieve an applied field strength $E = 1$ V/cm. Study 2: A section of native synovium was labeled with DiI (yellow) and placed in direct physical contact with native cartilage for EF stimulation. 10 mm diameter cylindrical explants (thickness of 1 mm), with 1mm diameter concentric cores removed, representing cartilage with a lesion were studied. Explants were cultured in serum-free chondrogenic defined media [8]. Imaging: For study 1, samples were stained with DAPI for cell localization. For study 2, the synovium was removed from the explant for subsequent fixation in 4% PFA and imaging, leaving migrated cells behind. Specimens were subsequently stained with DAPI (blue) for co-localization of endogenous cartilage cells with the migrated synovial cells on the cartilage explant. A confocal microscope was used to visualize cell accumulation at the cartilage surface and defect site. Chamber Characterization and Validation: Electrical properties of the specimens were computed assuming an applied current of 3.33 mA, media resistivity of 0.59 Ω m, cartilage resistivity of 1.56 Ω m, and sample geometry. Current density was 17 mA/cm² and voltage drop (E) was 1V/cm in the collagen gels in study 1. Current density was 422 mA/cm² and voltage drop (E) was 25 V/cm at the defect site for study 2. The overall chamber resistance was estimated theoretically and agreed with measurements. Finite element analysis of the configuration in study was also performed using FEBio, (Figure 1C and 1D) [1]. The cartilage ring was modeled as a triphasic material: porous solid (cartilage matrix), interstitial solvent (PBS/media), and two monovalent counter-ions (sodium and chloride) [2]. The current density profile at equilibrium showed high ion flow at the defect site and relatively low flow in the cartilage explant, as expected. Statistics: Comparisons were analyzed using ANOVA with Tukey's post-hoc test ($p < 0.05$).

RESULTS: In study 1, a proportion of synovial fibroblasts migrated to a maximum depth of ~250 μ m after 90 min and ~650 μ m after 180 min, for an average speed toward the cathode (-) in the range of 167 μ m/hr to 217 μ m/hr. For comparison, no-EF control cells migrated ~50 μ m/hr (Figure 2). For the given region of interest, ~11% of cells migrated after 90 min and ~23% in the 180 min sample. In study 2, a small number of synovial cells migrated to the cartilage surface regardless of treatment conditions. Control specimens (no-EF) showed minimal synovial cell recruitment to the cartilage surface (Figure 3A) and no visible migration into the defect site (Figure 3B). On the other hand, specimens exposed to a single three hour EF treatment showed a high degree of synovial cell recruitment (Figure 3C). Additionally, synovial cells migrated to a depth of up to 200 μ m into the defect after 180 min, for an average speed of ~66.7 μ m/hr (Figure 3D).




DISCUSSION: In the current study, a specialized galvanotaxis chamber was designed and tested to evaluate 3D cell migration to applied EF strengths at levels similar to those reported to promote galvanotaxis in 2D. The system was modeled and validated using finite element analysis and basic circuit computations. This study demonstrated enhanced cathodal migration of synovial repair cells in both a collagen gel scaffold and a cartilage explant defect repair model. Synovial fibroblasts have been shown to have a speed of up to 10 μ m/hr in 2D galvanotaxis systems ($E = 6$ V/cm) [4], whereas speeds of an order of magnitude greater were observed currently in 3D collagen gels (1 V/cm) and cartilage defects (25 V/cm). Cell sorting or passaging techniques may help to optimize the cell population for galvanotaxis and subsequent tissue repair [4]. While the present system is unable to perform real-time cell tracking, it does permit for maintenance of aseptic conditions, multiple treatments over time, and subsequent cell, tissue and media analyses. We anticipate that insights gained from the current studies may foster development of therapeutic strategies to promote endogenous cartilage repair by recruitment of resident or exogenously-delivered cells, such as synovial fibroblasts, via EF-induced homing.

SIGNIFICANCE: This chamber will allow subsequent studies to determine the optimal EF strength, electrode placement, and parameters of electrostimulation for cartilage repair, such as EFs to recruit or guide repair cells to the cartilage wound and then to stimulate their biosynthesis of tissue.

REFERENCES: [1] Maas+ J. *Biomech. Eng.* 2012. [2] Ateshian+ J. *Biomech. Eng.* 2013. [3] Chao+ *Connect. Tissue Res.* 2007. [4] Tan+ *OAC* 2015. [5]

Hunziker+ J *Bone Joint Surg.* 1996. [6] Sampat+ *Tissue Eng* 2011. [7] Balakatonis+ *Eplasty* 2008. [8] Ng+ *Annals Biomed Eng.* 2011.

ACKNOWLEDGEMENTS: This work was supported by CDMRP W81XWH-14-1-0591, NIH AR061988 and Columbia SURF-Amgen.



Overview – In Vitro Establishment of the Conditions For Use In Vivo in Canines

Acellular 2mg/ml collagen type I gel

200k P2 SDSCs seeded ON TOP

Cells allowed to adhere overnight

Following day, gels were placed in chamber on top of filter

3.33 mA applied for 0, 1.5, or 3 hr (**Field strength E: 1 V/cm**)- see calculations at end of slides

(***validated with measurements of chamber resistance**)

Afterwards, gels were fixed with PFA for 1 hour, stained with DAPI and imaged


Discussion

Cells seem to migrate at constant rate (325 μm traveled in 90 min, 650 μm in 180 min). However, a significant population stays at the top and does not migrate. This could be due to clustering of cells making it more difficult to move. Fix this and make easier to count by seeding a lower density? Also, how to count cells? Some issues with over-saturation in shallow areas of gel and under-saturation in deep areas, etc.

Note

Filters were removed from gels prior to imaging, so the two images (cells in gel and filter with/without cells) were pasted into the same image. They were resized and aligned to give an approximate view of where they were positioned in relation to each other during the experiment.

Control Gel (no electric field)




Cell penetration from
surface of acellular
gel: $\sim 140 \mu\text{m}$


Acellular Collagen Gel

Filter Membrane ($\sim 10 \mu\text{m}$
thickness) picks up DAPI
stain

90min electric field



180min electric
field



Population of cells remains
at gel surface



Acellular Collagen Gel

Cell penetration from
surface of acellular
gel: ~650 μm

Filter Membrane (~10 μm
thickness) picks up DAPI
stain. Some cells inside
filter (These may be the
same cells from above that
migrated into the gel)


Design changes needed for Transwell® configuration

- For same voltage drop in transwell configuration as in chamber; thus modified by using much thicker gel.
- For same current density (probably the more important factor)... need to increase current by factor of ~ 5.7 . This would lead to a current of ~ 19 mA (possible with current equipment, but joule heating may be an issue. With transwell configuration, 24 well transwell size would be better (much smaller cross-sectional area), but it is more difficult to place electrodes.




12 well Transwell® configuration

Control (5% FBS,
no current)




Cells illuminated with DAPI, appear to be nestled in pores of filter (which they were seeded onto)

5% FBS (3.33
mA, 1 V/cm)



Cells illuminated with DAPI, some cells appear to be pulled away from filter (on bottom) and up into collagen gel (above).

0.1% FBS



Cells illuminated with DAPI, some cells appear to be pulled away from filter (on bottom) and up into collagen gel (above).

OR130124 - Electric Field Stimulation Enhances Healing of Post-Traumatic Osteoarthritic Cartilage



PI: Bulinski, Jeannette Chloë, Ph.D. **Org:** Columbia University in the City of New York **Award Amount:** \$500K


Study Aims

- Test EF capacity to 'heal' wounds in canine cartilage explants.
- Test EF capacity to 'heal' cylindrical wound in cartilage explants as above, but with added synovium-derived stem cells (SDSCs).
- Test EF capacity to heal *in vivo* osteochondral defects in canine knees.
- Test EF capacity to heal *in vivo* canine cartilage defects as above but with added SDSCs that may home to wounds to promote healing.

Approach

In vitro studies: We will prepare cylindrical explants of canine knee cartilage, simulating a focal defect in canine cartilage. We will fill the centers with a gel of Type I collagen to simulate a fibrous scar. We will measure how well the applied EFs induce migration of chondrocytes and/or labeled SDSCs (added to ½ the explants) into the wound area of the explant.

In vivo studies: We will generate focal defects in the trochlear groove of canine knee cartilage and use applied EF to promote movement of endogenous chondrocytes and added canine SDSCs into the lesion. We will measure recovery of gait, arthroscopic imaging, and endpoint histology.



A) Apparatus we will use to A, Create cylindrical defects in cartilage explants with minimal cell death at wound edge (B, live cells: green and dead cells: red). Schematic of cartilage explant wound model subject to DC electric field (EF) ± SDSCs (C, D). E) Confocal stack image of cell migration (blue label) into cruciform wound on living cartilage explant (green chondrocytes). Not shown: Application of EFs to cylindrical defects made in canine knee cartilage (focal defect model), to promote migration of endogenous chondrocytes or injected SDSCs with the capacity to heal the cartilage.

Time and Cost

Activities	FY	14	15	16	17
Specific Aim 1 – apply EFs to canine cartilage explants to measure cell motility recruitment into an experimental wound.					
Specific Aim 2 – apply EFs to 'wounded' canine cartilage explants in the presence of SDSCs					
Specific Aim 3 – Perform <i>in vivo</i> studies investigating the efficacy of DC EFs for cartilage repair in a canine knee defect model					
Estimated Budget		\$110,594	\$169,802	\$220,687	

Goals/Milestones

FY14 Goal – Measurements of the efficacy of EFs to activate cell motility/recruitment into an experimental wound within canine cartilage explants (obtained from euthanized animals).

FY15 Goal – Measurements of the efficacy of EFs to activate motility/recruitment of Synovium-Derived Stem Cells (SDSCs) into experimental wounds within canine cartilage explants.

FY16 Goal – Testing the recovery of mechanical properties, biochemistry, and histology of canine knee joints which we treated with EF, SDSCs, both, or neither, to evaluate the efficacy of healing of *in vivo* cylindrical wounds (i.e., 'focal defect' lesions).

Comments/Challenges/Issues/Concerns

- N/A at this time

Total Budget Expenditure to Date

Actual Expenditure: \$338,417.94